Prednisone microencapsulated - Orbis Biosciences

Drug Profile

Prednisone microencapsulated - Orbis Biosciences

Alternative Names: ORB-101; Prednisone microencapsulated

Latest Information Update: 03 Mar 2016

Price : $50

At a glance

  • Originator Orbis Biosciences
  • Developer Childrens Mercy Hospital Kansas City; Orbis Biosciences
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Asthma; Atopic dermatitis; Bronchitis; Cancer; Eczema; Nephrotic syndrome

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jan 2016 Orbis completes a phase I trial in Healthy volunteers in USA (NCT02233959)
  • 01 Dec 2015 Phase-I clinical trials in Asthma (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top